araag2/HINT huggingface dataset:
Clinical trial NCT00144963 (phase 1/phase 2, status: completed)
Conditions: acute lymphoblastic leukemia
ICD codes: C91.01, C91.02, C91.00
Drugs: vincristine sulfate liposomes injection, dexamethasone
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Previously treated, relapsed or refractory ALL (including lymphoblastic lymphoma and
             Burkitt's subtypes) with measurable disease.

          -  Performance status ≤3 (ECOG).

          -  All ages are eligible. Those aged 12 years or older may be counted towards the MTD in
             the Phase I portion of the trial. Pediatric patients are eligible, but must be treated
             at a dose level previously tested in an adult (one full course).

          -  Adequate liver function (bilirubin ≤2 x upper limit normal), and renal function
             (creatinine ≤2 x upper limit normal).

          -  Negative pregnancy test in females of childbearing potential.

          -  Patients with prior history of stem cell transplant are eligible if they meet all
             other eligibility requirements.

        Exclusion Criteria:

          -  Active serious infection not controlled by oral or intravenous antibiotics.

          -  Treatment with any investigational agents or chemotherapy agents in the last 21 days
             before study entry, unless full recovery from side effects has occurred or the patient
             has rapidly progressive disease judged to be life threatening by the Investigator.

          -  Concurrent treatment with other anti-cancer agents other than dexamethasone.

          -  Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy
             or with CNS neuropathy limiting evaluation of study drug. Patients with controlled CNS
             disease (no progression signs or symptoms at the time of study entry) may be eligible
             after approval by the Principal Investigator. Lumbar puncture not required in
             asymptomatic patients.

          -  Prior history of Grade 3 or 4 sensory or motor neuropathy related to chemotherapeutic
             treatment, or persistent Grade 2 or greater active neuropathy.

          -  History of active neurologic disorders unrelated to chemotherapy (including familial
             neurologic diseases and acquired demyelinating disorders).

          -  Prior history of hypersensitivity reactions to vincristine or any of the other
             components of VSLI.

          -  Pregnant and/or lactating women; or fertile men or women not willing to use
             contraception.
Clinical trial NCT00099645 (phase 1/phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: mifepristone
SMILES: CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 infected

          -  CD4 count of 350 cells/mm3 or more within 90 days prior to study entry

          -  HIV-1 viral load of 2000 copies/ml or more within 90 days prior to study entry

          -  Willing to use acceptable forms of contraception during the study and for 30 days
             after stopping study medication

          -  If currently taking precautionary concomitant medications, must be on stable doses for
             more than 8 weeks prior to study entry and have no plans to change medications or
             doses for the duration of the study

          -  Body weight at least 40 kg (88 lbs) within 90 days prior to study entry

        Exclusion Criteria:

          -  Antiretroviral treatment (ART) within 16 weeks prior to study entry, or intend to
             start ART within 60 days after entry

          -  Adrenal disorders

          -  History of autoimmune endocrine disease in self or family

          -  History of active hepatitis B or C

          -  Current treatment for hepatitis B or C

          -  Moderate to severe liver disease

          -  Blood disorders or current anticoagulant therapy

          -  Prior pituitary tumor, surgery, radiation treatment, or pituitary failure

          -  Moderate to large goiters or thyroid nodules

          -  Diabetes mellitus

          -  Unusual uterine bleeding within 12 months prior to study entry

          -  Current hormonal contraception or intrauterine (IUD) use, including
             progesterone-containing vaginal rings

          -  Pregnancy within 90 days prior to study entry

          -  Breast-feeding

          -  Drugs that act as inhibitors or inducers of metabolism by cytochrome P450 3A4

          -  Systemic corticosteroids or hormonal agents within 90 days prior to study entry

          -  Any immunomodulator, HIV vaccine, or investigational therapy within 90 days prior to
             study entry

          -  Any vaccination within 30 days prior to study entry

          -  Systemic cytotoxic chemotherapy within 90 days prior to study entry

          -  History of allergy to mifepristone or the study formulations

          -  Current drug or alcohol abuse that, in the opinion of the investigator, may interfere
             with the study

          -  Any other conditions that may interfere with participant evaluation during the study

          -  Serious illness requiring systemic treatment or hospitalization. Patients who complete
             therapy or are clinically stable on therapy for at least 14 days prior to study entry
             are not excluded.
Clinical trial NCT01140412 (phase 1, status: terminated)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: maraviroc, fosamprenavir/ritonavir, maraviroc + fosamprenavir/ritonavir, maraviroc, fosamprenavir/ritonavir, maraviroc + fosamprenavir/ritonavir
SMILES: CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1, CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Reason stopped: 
    the trial prematurely terminated on november 1, 2010, due to healthy volunteer participants
    experiencing non-serious fosamprenavir-related skin rash.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.

          -  Total body weight >45 kg (99 lbs).

        Exclusion Criteria:

          -  History of regular alcohol consumption exceeding 14 drinks/week for females or 21
             drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of
             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.

          -  Use of tobacco- or nicotine-containing products in excess of the equivalent of 5
             cigarettes per day.

          -  Treatment with an investigational drug within 30 days (or as determined by the local
             requirement, whichever is longer) or 5 half-lives preceding the first dose of study
             medication.

          -  Known hypersensitivity or history of allergy to sulfonamides.
Clinical trial NCT00127101 (phase 1, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: vorinostat, comparator: bexarotene
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C
Reason stopped: 
    the study was stopped due to low enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Women or men greater than or equal to 18 years of age

          -  Advanced cutaneous T-cell lymphoma, stage IB or higher including Sezary Syndrome with
             progressive, persistent, or recurrent disease

          -  Failure of at least one systemic therapy, not including Bexarotene (Targretin)

          -  Eastern Cooperative Oncology Group (ECOG) status less than or equal to 2 (measurement
             to determine your ability to perform daily activities)

        Exclusion Criteria:

          -  Patient has had investigational treatment in the preceding 30 days

          -  Active hepatitis B or C, history of HIV

          -  Prior treatment with any HDAC inhibitor

          -  Patients must be disease free from prior malignancies for greater than 5 years, except
             for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma
             in-situ of the cervix
Clinical trial NCT00281476 (phase 1/phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: simvastatine
SMILES: [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
Eligibility criteria:

        Inclusion Criteria:

          -  multiple myeloma-patients in need of treatment

          -  stable og progressive disease

          -  age = or > 18 years

          -  performance status < 3

          -  life expectancy > 3 months

        Exclusion Criteria:

          -  pregnancy

          -  patients incapable of giving personally concent

          -  renal insufficiens with creatinine clearance below 25 ml/min

          -  alanin aminotransferasis > 2,5 x upper reference limit

          -  thyroxine below lower reference limit

          -  known familiar muscle-disease ar previous myopati

          -  creatinine kinase > 10 x upper reference limit

          -  medication with drugs with known interactions wiht simvastatine
Clinical trial NCT01725802 (phase 1/phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: levodopa and carbidopa solution for sc administration, placebo
SMILES: N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Men and women with idiopathic Parkinson's disease

          -  Subjects must experience motor fluctuations associated with LD/CD dosing

          -  Modified Hoehn and Yahr stage < 5

          -  Subjects must be taking optimized and stable levodopa/dopa decarboxylase inhibitor
             therapy

          -  Women must be postmenopausal, surgically sterilized, or using adequate birth control.
             Women of childbearing potential must have a negative pregnancy test (serum beta-HCG)
             at screening.

          -  Subjects must be age 30 or older.

          -  Subjects must be willing and able to give informed consent.

        Main Exclusion Criteria:

          -  Subjects with a clinically significant or unstable medical or surgical condition

          -  Subjects with clinically significant psychiatric illness.

          -  Pre-menopausal women, not using birth control method.

          -  Subjects who have taken experimental medications within 60 days prior to baseline.

          -  Subject who have undergone a neurosurgical intervention for Parkinson's disease (e.g.,
             pallidotomy, thalamotomy, transplantation and deep brain stimulation).
Clinical trial NCT01598740 (phase 1, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: clp, spironolactone
SMILES: CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Heart failure with New York Heart Association (NYHA) Classification II or III

          -  Chronic kidney disease

          -  Cardiac ejection fraction <40%

          -  On heart failure therapy including an ACEI or ARB, and a BB

          -  Willing to understand and comply with study procedures and provide written informed
             consent.

        Exclusion Criteria:

          -  Hospitalization within 4 weeks of baseline visit

          -  History or presence of gastrointestinal conditions such as severe constipation or
             gastrointestinal tract strictures

          -  Current or anticipated dialysis during study

          -  In the investigator's judgment, any cardiovascular, renal, hepatic, endocrine,
             gastrointestinal, neurological, or other disease or condition that makes the subject's
             study participation unsafe

          -  Drug or alcohol abuse
Clinical trial NCT01097681 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: asp1941
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetic patients for at least 12 weeks

          -  Fasting plasma glucose level of < 240 mg/dL

          -  Body Mass Index ( BMI )20.0 - 35.0kg/m2

          -  GFR value based on the Japanese GFR estimation equation at screening, of ≥ 30
             ml/min/1.73m2

        Exclusion Criteria:

          -  Type 1 diabetes mellitus patients

          -  Receiving insulin within 12 weeks before screening

          -  Diabetic ketoacidosis

          -  Dysuria and/or urinary tract infection, genital infection

          -  Significant renal, hepatic or cardiovascular diseases

          -  Severe gastrointestinal diseases
Clinical trial NCT00697476 (phase 1/phase 2, status: terminated)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: topotecan, vorinostat
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Reason stopped: 
    insufficient enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven diagnosis of SCLC;

          -  Limited or extensive-stage disease in patients who have received a single chemotherapy
             regimen or combined modality (chemotherapy + chest radiotherapy) regimen and relapsed
             after completion of first-line chemotherapy (sensitive relapse);

          -  Age >/= 18 years;

          -  ECOG Performance Status 0-2;

          -  Life expectancy of at least 12 weeks;

          -  Measurable lesions according to RECIST criteria;

          -  Adequate cardiac, hepatic, renal, and bone marrow function;

          -  Written informed consent.

        Exclusion Criteria:

          -  Prior treatment with an HDAC inhibitor;

          -  Symptomatic and/or unstable pre-existing brain metastases;

          -  Superior Vena Cava Syndrome;

          -  Spinal cord compression;

          -  Severe or uncontrolled medical diseases (Hypertension, diabetes, congestive heart
             failure, myocardial infarction within 6 months of study, chronic renal disease, or
             active uncontrolled infections);

          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with
             the exception of basal cell carcinoma or cervical cancer in situ;

          -  Pregnant or breastfeeding women.
Clinical trial NCT00445458 (phase 1/phase 2, status: completed)
Conditions: advanced breast cancer, advanced malignant solid tumors, breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: hki-272, paclitaxel
SMILES: CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

        Inclusion criteria for both parts of clinical trial:

          -  Good performance status

          -  Normal ejection fraction

          -  Adequate cardiac, kidney, and liver function

          -  Adequate blood counts

          -  At least one measurable target lesion

          -  Negative pregnancy test for female subjects

        Inclusion Criteria for Part 1 Only:

        - Pathologically confirmed solid tumor not curable with available standard therapy

        Inclusion Criteria for Part 2 Only:

          -  Pathologically confirmed breast cancer

          -  HER2 positive tumor

          -  Prior treatment with Herceptin

        Exclusion Criteria:

        Exclusion criteria for both parts of clinical trial:

          -  Major surgery, radiotherapy, chemotherapy or investigational agents within two weeks
             of treatment day 1

          -  Subjects with bone or skin as the only site of disease

          -  Active central nervous system metastases

          -  Significant cardiac disease or dysfunction

          -  Significant gastrointestinal disorder

          -  Inability or unwillingness to swallow HKI-272 capsules

          -  Prior exposure to HKI-272 or other HER2 targeted agents, except trastuzumab (Part 2
             only). Prior lapatinib is permitted in arm B of part 2.

          -  Treatment with a taxane within 3 months of treatment day 1

          -  Grade 2 or greater motor or sensory neuropathy

          -  Pregnant or breast feeding women

          -  Known hypersensitivity to paclitaxel or Cremophor EL

          -  Prior treatment with anthracyclines with cumulative dose of >400 mg/m^2

          -  Any other cancer within 5 years with the exception of contralateral breast cancer,
             adequately treated cervical carcinoma in situ, or adequately treated basal or squamous
             cell carcinoma of the skin

        Exclusion Criteria for Part 2 Only:

        - More than 1 (arm A) or 3 (arm B) prior cytotoxic chemotherapy regimen for metastatic
        disease
Clinical trial NCT00595686 (phase 1, status: completed)
Conditions: hematologic neoplasms
ICD codes: E70.338, E70.339, P09.3, O28.0, P61.8, P61.9, T45.8X1A
Drugs: snx-5422
SMILES: CC1(C)CC2=C(C(=NN2C2=CC(N[C@H]3CC[C@@H](CC3)OC(=O)CN)=C(C=C2)C(N)=O)C(F)(F)F)C(=O)C1
Eligibility criteria:

        Inclusion Criteria:

          -  >18 years old

          -  Karnofsky performance status > 60

          -  confirmed hematological malignancy

          -  refractory to available therapy or for which no therapy is available

          -  adequate hepatic, renal and hematological function

        Exclusion Criteria:

          -  CNS malignancy

          -  at risk for prolonged QT interval

          -  significant GI/liver disease

          -  other serious concurrent illness or medical condition
Clinical trial NCT01391117 (phase 1, status: terminated)
Conditions: hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: placebo., placebo., tmc649128., placebo., placebo, tmc649128, tmc649128., tmc649128, tmc649128., placebo.
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    antiviral activity was considered insufficient to warrant further clinical development of
    tmc649128.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Documented chronic (> 6 months) genotype 1a or 1b Hepatitis C virus (HCV) infection

          -  Treatment-naive volunteer, meaning never received (Peg)IFN, RBV or any other approved
             or investigational treatment for chronic HCV infection (Panels 1, 2, 3 or 4) OR
             volunteer is a documented prior non-responder or relapser subject to previous
             treatment regimens (IFN/RBV or pegylated IFN/RBV) but has stopped this treatment at
             least 6 months before screening

          -  volunteer has never received a HCV polymerase inhibitor and HCV protease inhibitor
             treatment was stopped since at least one year (Panels 1, 2 or 3)

          -  Volunteer with HCV plasma RNA levels of > 100,000 IU/mL at screening

          -  Body Mass Index of 18.0 to 35.0 kg/m2

          -  Healthy based on a medical evaluation including medical history, physical examination,
             blood tests, vital signs, and electrocardiogram.

        Exclusion Criteria:

          -  Evidence of liver cirrhosis

          -  Historical liver biopsy graded as liver cirrhosis or evidence for the presence of
             oesophageal varices or a transient elastography (Fibroscan) result of more than 14.6
             kPa within 2 years prior to screening

          -  Evidence of decompensated liver disease defined as prior history or current evidence
             of ascites, hepatic encephalopathy, bleeding oesophageal or gastric varices

          -  Evidence of renal dysfunction, documented by an estimated creatinine clearance below
             70 mL/min

          -  Evidence of any other cause of significant liver disease in addition to hepatitis C,
             this may include but is not limited to hepatitis B, drug- or alcohol-related
             cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic
             steatohepatitis, or primary biliary cirrhosis

          -  Volunteer with diagnosed or suspected hepatocellular carcinoma

          -  Volunteer receiving or having received any treatment for HCV during the 6 months
             before screening

          -  Volunteer coinfected with Human Immunodeficiency Virus-1 (HIV-1) or HIV-2, or
             hepatitis A or B virus infection, or clinically active tuberculosis at study
             screening.